Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2019 Jan 3.

Published in final edited form as: J Clin Immunol. 2017 Jul 28;37(6):548–558. doi: 10.1007/s10875-017-0422-6

Table 2.

Overall and event-free survival, univariate analysis

	Overall survival	Event-free survival
Age	0.634	0.847
Sex	0.413	0.333
Clinical disease^a	0.128	0.400
Busulfan AUC (min*microm/L)	0.136	0.254
Total nucleated cell dose	0.630	0.844
CD34+ cell dose	0.985	0.669
CD3+ cell dose	0.934	0.476
Day 30 myeloid chimerism	0.245	0.034
Day 30 CD3+ chimerism	0.764	0.548
Day 30 NK chimerism	0.593	0.023
Day 100 myeloid chimerism	0.033	<0.0001
Day 100 CD3+ chimerism	0.902	0.325
Day 100 NK chimerism	0.024	0.008

^a

Clinical disease includes the categories infectious, inflammatory, or mixed